stoxline Quote Chart Rank Option Currency Glossary
  
Mainz Biomed B.V. (MYNZ)
1.115  -0.015 (-1.33%)    12-08 16:00
Open: 1.13
High: 1.21
Volume: 255,509
  
Pre. Close: 1.13
Low: 1.07
Market Cap: 23(M)
Technical analysis
2023-12-08 4:44:53 PM
Short term     
Mid term     
Targets 6-month :  2.9 1-year :  3.96
Resists First :  2.48 Second :  3.39
Pivot price 1.17
Supports First :  1.02 Second :  0.85
MAs MA(5) :  1.22 MA(20) :  1.23
MA(100) :  2.74 MA(250) :  4.64
MACD MACD :  -0.3 Signal :  -0.3
%K %D K(14,3) :  11.1 D(3) :  20.3
RSI RSI(14): 37.9
52-week High :  8.21 Low :  1.02
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ MYNZ ] has closed above bottom band by 37.6%. Bollinger Bands are 59% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.21 - 1.22 1.22 - 1.22
Low: 1.05 - 1.06 1.06 - 1.07
Close: 1.1 - 1.11 1.11 - 1.12
Company Description

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.

Headline News

Wed, 06 Dec 2023
Mainz Biomeds ColoAlert A Groundbreaking Advancement in Colorectal Cancer Diagnostics - Best Stocks

Tue, 05 Dec 2023
Mainz Biomed Unveils Groundbreaking Findings on Enhanced ColoAlert for Colorectal Cancer Detection - Best Stocks

Mon, 27 Nov 2023
Where Will Mainz Biomed NV (MYNZ) Stock Go Next After It Is Down 5.79% in a Week? - InvestorsObserver

Fri, 24 Nov 2023
Mainz Biomed NV (MYNZ) Stock Falls -0.87% This Week; Should You Buy? - InvestorsObserver

Thu, 23 Nov 2023
FY2023 EPS Estimates for Mainz Biomed (NASDAQ:MYNZ) Raised by HC Wainwright - Defense World

Tue, 21 Nov 2023
Ceapro (OTCMKTS:CRPOF) and Mainz Biomed (NASDAQ:MYNZ) Critical Analysis - Defense World

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Diagnostics & Research
Shares Out 0 (M)
Shares Float 20 (M)
Held by Insiders 1.478e+007 (%)
Held by Institutions 23.7 (%)
Shares Short 110 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -2.819e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -3 %
Return on Assets (ttm) 104.9 %
Return on Equity (ttm) -93.5 %
Qtrly Rev. Growth 874000 %
Gross Profit (p.s.) 127.1
Sales Per Share -484.06
EBITDA (p.s.) 0
Qtrly Earnings Growth -2 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -22 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow 3.66
Stock Dividends
Dividend 0
Forward Dividend 138550
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android